Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The awards cover 23,550 shares total, have a 10-year term, a $17.57 exercise price, and time-based vesting tied to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CBIO
-2.29%
3 alerts
-2.29%Session close to close
+2.4%Peak Tracked
$524.97MMarket Cap
0.3xRel. Volume
In the Jun 12 session, CBIO declined 2.29%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +2.4% during that session.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This announcement details routine hiring-related equity grants: options on 23,550 shares with a 10-y...
Analysis
This announcement details routine hiring-related equity grants: options on 23,550 shares with a 10-year term and a $17.57 exercise price, vesting over four years. It adds modest, structured dilution tied to employee retention rather than financing. In context of prior inducement awards and recent clinical and investor-relations updates, key items to watch remain trial progress, future financing actions, and how compensation levels track against pipeline milestones and cash of $189.2 million.
Key Figures
Current share price:$17.57Inducement option size:23,550 sharesOption term:10 years+5 more
8 metrics
Current share price$17.57Closing price used as option exercise price on June 10, 2026
Inducement option size23,550 sharesAggregate options granted to two non-executive employees
Option term10 yearsLife of the inducement stock options
Initial vesting25% at 1 yearOne-fourth of shares vest on first anniversary of start date
Ongoing vesting1/48 monthlyRemaining shares vest monthly thereafter, subject to service
Cash & equivalents$189.2 millionBalance as of March 31, 2026 from recent 8-K
Net loss$23.3 millionQ1 2026 net loss, or $0.70 per share
Q1 2026 revenue$1.0 millionReported in April 29, 2026 8-K
Announced management presentations at three May 2026 conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent CBIO news often coincided with modest price moves, mostly aligned with neutral-to-positive catalysts, with one small divergence.
Recent Company History
Over the past months, Crescent Biopharma has alternated between corporate updates, pipeline progress, and employee equity grants. Investor conference announcements on May 6 and June 2 tied to fireside chats and presentations, with the latter seeing a 5.73% gain. Inducement option grants on May 12 and May 29 covered 129,075 and 16,950 shares, respectively, and produced mixed price reactions. A notable clinical milestone was the ASCEND Phase 1/2 CR-001 trial-in-progress update on May 21, after which shares rose 2.52%.
"to two non-executive employees as equity inducement awards under the Crescent"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
exercise pricefinancial
"a 10-year term and an exercise price equal to $17.57, the closing price per"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Nasdaq Listing Rule 5635(c)(4)regulatory
"with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4). The options"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 23,550 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on June 10, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $17.57, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on June 10, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
What inducement awards did Crescent Biopharma (CBIO) grant on June 10, 2026?
Crescent Biopharma granted stock options to purchase an aggregate 23,550 ordinary shares as equity inducement awards to two non-executive employees. According to the company, these options were approved under its 2025 Employment Inducement Incentive Award Plan, as amended, to support new hires.
What is the exercise price and term of the new Crescent Biopharma (CBIO) inducement options?
The inducement options have an exercise price of $17.57 per share and a 10-year term. According to Crescent, the exercise price equals the June 10, 2026 Nasdaq closing price for its ordinary shares, aligning the awards with the market value at grant.
How do the Crescent Biopharma (CBIO) inducement stock options vest for new employees?
The options vest 25% on the first anniversary of each employee’s start date, then 1/48 monthly thereafter. According to Crescent, vesting is subject to continuous service through the applicable vesting dates, encouraging longer-term employee retention and alignment with shareholders.
Why were Crescent Biopharma (CBIO) inducement awards important for the new employees?
The company states the options were material to each employee’s acceptance of employment with Crescent. According to Crescent, these equity awards support talent recruitment while complying with Nasdaq Listing Rule 5635(c)(4) for inducement grants outside shareholder-approved plans.
Under which plan were Crescent Biopharma (CBIO) inducement options granted?
The stock options were granted under the Crescent Biopharma 2025 Employment Inducement Incentive Award Plan, as amended. According to the company, the awards are also governed by individual option agreements that specify detailed terms and conditions for each grant.
